Ballicules.com

Tiotropium

SPIRIVA

What it isLong-acting muscarinic antagonist bronchodilator; COPD maintenance and add-on asthma treatment.

Why this oneIt has the longest clinical track record among LAMAs, and its soft-mist formulation also carries an asthma indication.

What limits itDry mouth, urinary retention, and glaucoma can worsen; it is maintenance only, and powder capsules must be inhaled, not swallowed.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
COPD, maintenanceAdultsTwo inhalations of one 18 mcg capsule QD18 mcg QD

Renal No adjustment needed; monitor closely for anticholinergic effects if CrCl <60 mL/min

Hepatic No adjustment needed (not studied)

Do not exceed one dose (two inhalations) per 24 hours

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Limited human data insufficient to inform risk

Lactation No human data; present in milk of lactating rats

NO BOXED WARNINGS

Principal riskAnticholinergic effects; acute urinary retention

Cost, est. cash$30–$500/month

Generic entry2023

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism4 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityTremor, tachycardia or anticholinergic effects; excessive beta-agonist exposure can cause hypokalemia and arrhythmia.

Mechanism of action: Tiotropium ballicule

Tiotropium ballicule: receptor binding, kinetics and half-life diagram

Open Tiotropium in the interactive console ↗

Memory aids: mascots and interaction avatars

Tiotropium SPIRIVA mascot mnemonic cartoon
“Tio’s tropical Spiral”
red as a beet” → anticholinergic

Open Tiotropium in the interactive console ↗